Skip to main content
OpenTrials
Completed

NCT Number: NCT05679765

Efficacy of GONB in Patients of Migraine

The study was carried to determine the analgesic efficacy of greater occipital nerve block in patients of migraine. It was a randomised controlled which took place from april 2022 - october 2022. Fifty patients suffering from migraine were included in the study. Patients in Group G were given greater occipital nerve block (GONB) with lignocaine and dexamethasone under ultrasound guidance while those in Group S were given saline 0.9% as placebo. Pain score using Numeric Rating Scale and number of headache days was assessed at four,eight and twelve weeks after the procedure as a primary outcome. Total headache days were recorded as a secondary outcome.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Chronic Migraine Headache Neurologic Manifestations Pain Pathological Conditions, Signs and Symptoms Signs and Symptoms

Age range

18 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Pain Medicine Department

Lahore, Pakistan

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients between 18 to 60 years
  • diagnosed case of migraine

Exclusion criteria

  • Patients with known allergies to local anaesthetics
  • pregnancy
  • history of cranial or cervical surgery
  • head injury
  • headaches secondary to medication overuse
  • patients with uncontrolled systemic disease like blood pressure, diabetes mellitus
  • hypo or hyperthyroidism
  • patient who had already received GONB or botulinum toxin type A therapy within last 6 months
  • major psychiatric disorder
  • history of chronic pain syndromes

Treatment and study plan

Greater Occipital Nerve Block with dexamethasone and lidocaine

Drug

Ultrasound guided Greater occipital nerve block on the side of headache

Other names: GONB with dexamethasone and lidocaine

Greater Occipital Nerve Block with 0.9% saline

Drug

Ultrasound guided Greater occipital nerve block on the side of headache

Other names: GONB with 0.9% saline

Primary outcomes

  1. Analgesic efficacy

    Time frame: 12 weeks

    Change in Pain score assessed on Numeric Rating Scale (NRS) which ranges from 0 to 10. 0 is no pain and 10 is maximum pain.

Secondary outcomes

  1. Headache days

    Time frame: 12 weeks

    Number of headache days over the course of study period.

Sponsors and collaborators

Lead sponsor

Pain Medicine Department

Other

Registry information

Official study title

Analgesic Efficacy of Ultrasound-guided Greater Occipital Nerve Block in Patients of Chronic Migraine

Important dates

Study start
2022
Primary completion
2022
Study completion
2022
First posted
Jan 11, 2023
Registry last updated
Jan 12, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.